EMERYVILLE, Calif.--(BUSINESS WIRE)-- Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced that Dr. Cheng Liu, President and Chief Executive Officer, is scheduled to participate at Oppenheimer’s Private Life Sciences Company Call Series on Monday, June 29, 2020.

Dr. Liu will be presenting the use of Eureka’s novel antibody-TCR receptor (ARTEMIS^® T cell) that has been engineered with a proprietary human TCR-mimic antibody to target the alpha fetoprotein (AFP)-peptide/HLA-A2 complex on HCC cancer cells.

About Eureka Therapeutics, Inc.

Eureka Therapeutics, Inc. is a privately held clinical stage biotechnology company focused on developing novel T cell therapies to treat cancers. Its core technology centers around its proprietary ARTEMIS^® AbTCR T cell receptor platform and E-ALPHA^® antibody discovery platform for the discovery and development of potentially safer and more effective T cell therapies for the treatment of multiple solid and hematologic tumors. ET140202, the Company’s lead asset, is currently in a Phase I/II US multicenter clinical trial in patients with advanced hepatocellular carcinoma (HCC).

Eureka Therapeutics, Inc. is headquartered in the San Francisco Bay Area. For more information on Eureka, please visit www.eurekatherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200625005283/en/